Effects of ozanimod: A Synthesis of Findings from 15 Studies

  1. Home
  2. Effects of ozanimod
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of ozanimod: A Synthesis of Findings from 15 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of ozanimod: A Synthesis of Findings from 15 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Findings

Ozanimod is a new oral medication that has shown promise in treating moderately to severely active ulcerative colitis. 3 Ozanimod is a sphingosine-1-phosphate (S1P) receptor modulator that selectively targets S1P1 and S1P5 receptors. 9 Ozanimod is also used for treating clinically isolated syndrome, relapsing-remitting, and secondary progressive forms of multiple sclerosis (MS). 2 Ozanimod selectively modulates S1P1 and S1P5 receptors to prevent autoreactive lymphocytes from entering the central nervous system (CNS) where they can promote nerve damage and inflammation. 2 Ozanimod has been shown to be effective and well tolerated for treating MS. 2 However, ozanimod is associated with some complications such as an increased risk of infections, liver injury, fetal risk, increased blood pressure, respiratory effects, macular edema, and posterior reversible encephalopathy syndrome. 2 More research is needed to evaluate the efficacy of ozanimod compared with other S1P1 receptor modulators. 2 Ozanimod has also been shown to be safe for the heart in patients with ulcerative colitis. 3 In the case of multiple sclerosis, more research is needed to evaluate the efficacy and safety of ozanimod compared with other S1P1 receptor modulators. 2 More research is also needed to determine whether ozanimod has any effect on cognitive function in patients with MS. 14 Ozanimod may affect the immune response to SARS-CoV-2 vaccines in patients with MS. 10 Ozanimod may be a potential treatment for antibiotic-refractory chronic pouchitis in patients with ulcerative colitis. 6 Ozanimod should not be used in pregnant or breastfeeding women. 11 More research is needed to evaluate the cardiac safety of ozanimod in patients with ulcerative colitis. 1 In patients with multiple sclerosis, switching from fingolimod to ozanimod may be a strategy to adjust fingolimod-related lymphopenia. 5 Ozanimod may cause unique lymph node histological changes in patients with ulcerative colitis. 8 Ozanimod can cause cystoid macular edema in patients with ulcerative colitis.

Benefits and Risks

Benefits Summary

Ozanimod has shown promise in treating moderately to severely active ulcerative colitis. 3 Ozanimod is also used for treating clinically isolated syndrome, relapsing-remitting, and secondary progressive forms of multiple sclerosis (MS). 2 In patients with multiple sclerosis, switching from fingolimod to ozanimod may be a strategy to adjust fingolimod-related lymphopenia. 5

Risks Summary

Ozanimod is associated with some complications such as an increased risk of infections, liver injury, fetal risk, increased blood pressure, respiratory effects, macular edema, and posterior reversible encephalopathy syndrome. 2 More research is needed to evaluate the cardiac safety of ozanimod in patients with ulcerative colitis. 1 Ozanimod may cause unique lymph node histological changes in patients with ulcerative colitis. 8 Ozanimod can cause cystoid macular edema in patients with ulcerative colitis.

Comparison of Studies

Similarities of Studies

These studies show that ozanimod is a promising treatment for both ulcerative colitis and multiple sclerosis. 3 2 Ozanimod works by selectively modulating S1P1 and S1P5 receptors to regulate immune cell function. 2 9

Differences of Studies

These studies highlight the need for more research on the cardiac safety, cognitive function, immune response to SARS-CoV-2 vaccines, and safety during pregnancy or breastfeeding in patients taking ozanimod. 3 2 14 10 11

Consistency and Discrepancies of Results

These studies indicate that ozanimod is effective for treating ulcerative colitis and multiple sclerosis but more research is needed on the cardiac safety, cognitive function, immune response to SARS-CoV-2 vaccines, and safety during pregnancy or breastfeeding in patients taking ozanimod. 3 2 14 10 11

Implications for Everyday Life

Ozanimod is a new oral medication that has shown promise in treating moderately to severely active ulcerative colitis. 3 Ozanimod is also used for treating clinically isolated syndrome, relapsing-remitting, and secondary progressive forms of multiple sclerosis (MS). 2 If you are considering taking ozanimod, it is important to discuss the potential risks and benefits with your doctor. 2

Limitations of Current Research

These studies are relatively small and more research is needed. 3 2 More research is needed on the cardiac safety, cognitive function, immune response to SARS-CoV-2 vaccines, and safety during pregnancy or breastfeeding in patients taking ozanimod. 3 2 14 10 11

Future Research Directions

More research is needed on the cardiac safety, cognitive function, immune response to SARS-CoV-2 vaccines, and safety during pregnancy or breastfeeding in patients taking ozanimod. 3 2 14 10 11 More research is also needed to evaluate the efficacy and safety of ozanimod compared with other S1P1 receptor modulators. 2

Conclusion

Ozanimod is a promising new oral medication for treating moderately to severely active ulcerative colitis and multiple sclerosis. 3 2 However, more research is needed on the cardiac safety, cognitive function, immune response to SARS-CoV-2 vaccines, and safety during pregnancy or breastfeeding. 3 2 14 10 11 If you are considering taking ozanimod, talk to your doctor about the potential risks and benefits. 2

Literature analysis of 15 papers
Positive Content
14
Neutral Content
1
Negative Content
0
Article Type
0
1
1
4
14
2.

Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.

Author: LassiterGrace, MelanconCarlie, RooneyTyler, MuratAnne-Marie, KayeJessica S, KayeAdam M, KayeRachel J, CornettElyse M, KayeAlan D, ShahRutvij J, ViswanathOmar, UritsIvan

Effective treatment
Well-tolerated
Fetal risk
Increased blood pressure
Infections
Liver injury
Macular edema
Posterior reversible encephalopathy syndrome
Respiratory effects

Ozanimod is a novel S1P receptor modulator approved for the treatment of multiple sclerosis (MS). This abstract discusses the efficacy and safety of ozanimod, highlighting its potential benefits and risks. Further research is needed to compare ozanimod with other S1P1 receptor modulators.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

3.

Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.

Author: ArmuzziAlessandro, CrossRaymond K, LichtensteinGary R, HouJason, DeepakParakkal, RegueiroMiguel, WolfDouglas C, AkukweLucy, AhmadHarris A, JainAnjali, KozinnMarc, WuHsiuanlin, PetersenAnnKatrin, CharlesLorna, LongMillie

Cardiovascular safety

This analysis reports the cardiovascular safety of ozanimod, an S1P receptor modulator, in patients with moderately to severely active ulcerative colitis from the phase 3 True North (TN) and open-label extension (OLE) trials.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.

Author: TramacereIrene, VirgiliGianni, PerducaVittorio, LucenteforteErsilia, BenedettiMaria Donata, CapobussiMatteo, CastelliniGreta, FrauSerena, Gonzalez-LorenzoMarien, FeatherstoneRobin, FilippiniGraziella

Decreased disease activity
MS treatment
Safety uncertainty
Significant disability

Multiple sclerosis (MS) is a disease affecting the brain and spinal cord, primarily affecting young adults, with women being affected more often than men. While treatments for MS can slow the disease's progression, there's still uncertainty about their safety.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia.

Author: CaliendoDaniele, GrassiaMaria Carmela, CarotenutoAntonio, PetraccaMaria, LanzilloRoberta, Brescia MorraVincenzo, MocciaMarcello

MS treatment
Lymphopenia

This study aims to assess the feasibility of switching from fingolimod to ozanimod in patients with multiple sclerosis (MS) to manage fingolimod-related lymphopenia while maintaining clinical efficacy.

LetterA written message for communication and exchange of information between individuals.

Language : English

6.

Treatment of antibiotic refractory chronic pouchitis with JAK inhibitors and S1P receptor modulators: an ECCO CONFER Multicentre Case Series.

Author: RibaldoneDavide Giuseppe, TestaGiulia, VerstocktBram, MolnarTamas, SavarinoEdoardo, SchmidtCarsten, VieujeanSophie, TeichNiels, MeianuCorina, JuilleratPascal, GrellierNathan, LobatonTriana

CARP treatment

Small molecules, such as JAK inhibitors and S1P receptor modulators, may represent a suitable option for chronic pouchitis refractory to multiple biologics. In a retrospective study of 15 patients, 53.3% achieved a clinical response and 40% achieved clinical remission after 3 months of treatment with JAK inhibitors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

12.

S1PR-1/5 modulator RP-101074 shows beneficial effects in a model of central nervous system degeneration.

Author: SindiMustafa, HeckerChristina, IssbernerAndrea, RuckTobias, MeuthSven G, AlbrechtPhilipp, DietrichMichael

Positive effects in progressive MS

Selective sphingosine-1-phosphate receptor S1PR-1 and -5 modulators show potential for treating progressive multiple sclerosis (MS), targeting inflammation-driven neurodegeneration and demyelination. Further research is needed to explore their efficacy and safety in this specific context.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis.

Author: CreeBruce A C, MadduxRachel, Bar-OrAmit, HartungHans-Peter, KaurAmandeep, BrownElizabeth, LiYicong, HuYanhua, SheffieldJames K, SilvaDiego, HarrisSarah

COVID-19 recovery
Serological response

Ozanimod-treated participants with RMS mounted a serologic response to SARS-CoV-2 vaccination and infection. All COVID-19-related AEs post-full vaccination were nonserious and not severe.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review.

Author: CarlomagnoVincenzo, MirabellaMassimiliano, LucchiniMatteo

Cognitive impairment treatment

This review examines the current evidence on the effects of oral disease-modifying treatments (DMTs) on cognitive function in patients with multiple sclerosis (MS). The review highlights the need for standardized cognitive evaluations and further research to understand the impact of DMTs on cognitive outcomes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.